These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 18980973)
1. BRCA1 5083del19 mutant allele selectively up-regulates periostin expression in vitro and in vivo. Quaresima B; Romeo F; Faniello MC; Di Sanzo M; Liu CG; Lavecchia A; Taccioli C; Gaudio E; Baudi F; Trapasso F; Croce CM; Cuda G; Costanzo F Clin Cancer Res; 2008 Nov; 14(21):6797-803. PubMed ID: 18980973 [TBL] [Abstract][Full Text] [Related]
2. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers. Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154 [TBL] [Abstract][Full Text] [Related]
3. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo. Quaresima B; Faniello MC; Baudi F; Crugliano T; Di Sanzo M; Cuda G; Costanzo F; Venuta S Oncol Rep; 2006 Oct; 16(4):811-5. PubMed ID: 16969499 [TBL] [Abstract][Full Text] [Related]
4. Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation? Russo A; Calò V; Bruno L; Schirò V; Agnese V; Cascio S; Foddai E; Fanale D; Rizzo S; Di Gaudio F; Gulotta E; Surmacz E; Di Fede G; Bazan V Breast Cancer Res Treat; 2009 Jan; 113(1):67-70. PubMed ID: 18228134 [TBL] [Abstract][Full Text] [Related]
5. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Pinilla SM; Honrado E; Hardisson D; Benítez J; Palacios J Breast Cancer Res Treat; 2006 Sep; 99(1):85-90. PubMed ID: 16541313 [TBL] [Abstract][Full Text] [Related]
6. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Elstrodt F; Hollestelle A; Nagel JH; Gorin M; Wasielewski M; van den Ouweland A; Merajver SD; Ethier SP; Schutte M Cancer Res; 2006 Jan; 66(1):41-5. PubMed ID: 16397213 [TBL] [Abstract][Full Text] [Related]
7. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573 [TBL] [Abstract][Full Text] [Related]
8. The expression analysis of periostin in human breast cancer. Zhang Y; Zhang G; Li J; Tao Q; Tang W J Surg Res; 2010 May; 160(1):102-6. PubMed ID: 19524268 [TBL] [Abstract][Full Text] [Related]
9. Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair--perhaps through transcription. Somasundaram K J Cell Biochem; 2003 Apr; 88(6):1084-91. PubMed ID: 12647291 [TBL] [Abstract][Full Text] [Related]
10. Breast cancer cell response to genistein is conditioned by BRCA1 mutations. Privat M; Aubel C; Arnould S; Communal Y; Ferrara M; Bignon YJ Biochem Biophys Res Commun; 2009 Feb; 379(3):785-9. PubMed ID: 19126406 [TBL] [Abstract][Full Text] [Related]
11. Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis. Yeung BH; Kwan BW; He QY; Lee AS; Liu J; Wong AS Oncogene; 2008 Dec; 27(53):6782-9. PubMed ID: 18776923 [TBL] [Abstract][Full Text] [Related]
12. The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors. Winter SL; Bosnoyan-Collins L; Pinnaduwage D; Andrulis IL BMC Cancer; 2007 May; 7():85. PubMed ID: 17511879 [TBL] [Abstract][Full Text] [Related]
13. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Melchor L; Honrado E; García MJ; Alvarez S; Palacios J; Osorio A; Nathanson KL; Benítez J Oncogene; 2008 May; 27(22):3165-75. PubMed ID: 18071313 [TBL] [Abstract][Full Text] [Related]
14. Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells. Sirchia SM; Ramoscelli L; Grati FR; Barbera F; Coradini D; Rossella F; Porta G; Lesma E; Ruggeri A; Radice P; Simoni G; Miozzo M Cancer Res; 2005 Mar; 65(6):2139-46. PubMed ID: 15781624 [TBL] [Abstract][Full Text] [Related]
15. Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets. Drikos I; Nounesis G; Vorgias CE Proteins; 2009 Nov; 77(2):464-76. PubMed ID: 19452558 [TBL] [Abstract][Full Text] [Related]
16. Cyclosporine A inhibition of prolactin-dependent up-regulation of BRCA1 protein expression in human breast cell lines. Favy DA; Rio PG; Vissac C; Maurizis JC; Bignon YJ; Bernard-Gallon DJ Anticancer Res; 2000; 20(3A):1703-4. PubMed ID: 10928095 [TBL] [Abstract][Full Text] [Related]
17. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. DelloRusso C; Welcsh PL; Wang W; Garcia RL; King MC; Swisher EM Mol Cancer Res; 2007 Jan; 5(1):35-45. PubMed ID: 17259345 [TBL] [Abstract][Full Text] [Related]
18. Cancer-related mutations in BRCA1-BRCT cause long-range structural changes in protein-protein binding sites: a molecular dynamics study. Gough CA; Gojobori T; Imanishi T Proteins; 2007 Jan; 66(1):69-86. PubMed ID: 17063491 [TBL] [Abstract][Full Text] [Related]
19. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells. Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673 [TBL] [Abstract][Full Text] [Related]